Arizona Is Winning the Opioid Fight It Built and Losing the Meth-and-Heat Crisis It Didn’t

In the 12 months ending September 2025, Arizona logged a 17% rise in overdose deaths while the national count fell 21% — the largest state-level increase anywhere in the country, and one of only five states to move in the wrong direction at all, per an Axios Phoenix analysis published July 23. The DEA’s Phoenix Field Division seized 79% more fentanyl powder in 2025 than the year before. Arizona’s overdose rate hit an all-time high: 43.5 per 100,000.

Set that beside Arizona’s own county data and it reads like a contradiction. Opioid-specific overdoses fell more than 50% year-over-year in Maricopa, Pima, and Pinal counties, with Maricopa County alone recording more than 2,300 fewer overdoses, according to AZDHS figures reported by FOX 10 Phoenix in mid-June.

Arizona is winning the fight it built infrastructure for and losing the one it didn’t see coming.

These aren’t the same measurement, and treating them as one contradicts the actual story. The FOX 10 figure is opioid-specific mortality in three counties. The Axios figure is all-drug mortality statewide, over a different twelve-month window. Both can be true because Arizona’s crisis has a second engine now, and it isn’t opioids.

Methamphetamine was involved in roughly 60.5% of Arizona’s overdose deaths in 2024 — 1,655 deaths — and it interacts with something naloxone and buprenorphine were never built to touch: 110-degree summer heat, per KJZZ’s August 4 reporting. Meth raises body temperature and heart rate; heat, dehydration, and sleep loss intensify both. And 80-90% of Arizona’s fentanyl users also use meth, meaning the same person driving the state’s fentanyl-seizure numbers up is often also carrying the drug naloxone can’t reverse.

That’s the gap. Arizona’s opioid response — naloxone saturation, MOUD access, the infrastructure behind those 50% county declines — was built correctly for opioids and is producing exactly the results it should. None of it does anything for a stimulant overdose. There is no FDA-approved medication for methamphetamine use disorder equivalent to buprenorphine. Naloxone reverses opioid respiratory depression; it does nothing for meth-driven hyperthermia and cardiac strain in a state where July highs regularly clear 110 degrees. Arizona built a very good opioid response during the exact window meth became the state’s dominant killer, and the tools don’t transfer.

The state isn’t facing one overdose crisis. It’s facing the tail end of one it already tamed and the early, undersupplied years of another — arriving every July with the heat.